Ph.D., Chief Science Officer, AccuGenomics, Inc.
Dr. Morrison’s experience and leadership further AccuGenomics’ goals in internal standard development and optimization, commercial product development and launch, and development of a strong product pipeline. Dr. Morrison is currently leading the development of Standardized Nucleic Acid Quantification (SNAQ), which include the FDA clinical trial for SNAQ BCR-ABL1 qPCR kit and bringing the SNAQ technology to NGS. Dr. Morrison has more than 15 years of experience developing and commercializing technologies in emerging and mid-sized Life Sciences companies, with an emphasis on diagnostics testing market and technologies in the last eight years. Prior to joining AccuGenomics, Dr. Morrison served as Senior Director at BioTrove (now part of LifeTechnologies), a nanoplate-based genomics company. Previous to this role he was director of protein engineering at the industrial enzyme company Genencor. Dr. Morrison received his Ph.D. from the University of Utah, Salt Lake City and his B.A. from University of California, Berkeley.
Presentation Title and Company Description
Clinical Dx Showcase: SNAQ-SEQ Spike-in Controls Provide Needed NGS QC
AccuGenomics unique spike-in controls provide direct NGS QC information for every actionable mutation in every clinical sample. Controls enable estimations of variant allele LoD, confidence interval, and digital PCR-like accuracy for CNV or transcript abundance measurements.